Hepatitis C Virus: Epidemiology Report and Forecast to 2035

Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue, abdominal pains, fever, nausea, vomiting, and jaundice (Fasano et al., 2024; NHS, 2021a). Acute infection refers to infections lasting for up to six months after infection, and of these infections approximately 30% undergo spontaneous clearance. The remaining 70% of cases that last over six months develop into chronic hepatitis C, which can result in cirrhosis and hepatocellular carcinoma (HCC) if left untreated (Fasano et al., 2024; NHS, 2021a).

Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs (PWID), unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue, abdominal pains, fever, nausea, vomiting, and jaundice (Fasano et al., 2024; NHS, 2021a). Acute infection refers to infections lasting for up to six months after infection, and of these infections approximately 30% undergo spontaneous clearance. The remaining 70% of cases that last over six months develop into chronic hepatitis C, which can result in cirrhosis and hepatocellular carcinoma (HCC) if left untreated (Fasano et al., 2024; NHS, 2021a). According to the World Health Organization (WHO), an estimated 50 million people have chronic hepatitis C infection globally, with approximately one million cases occurring per year (WHO, 2025a).

Scope

• The Hepatitis C Virus: Epidemiology Report and Forecast Model provide an overview of the risk factors, comorbidities, and global trends of Hepatitis C in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
• The report includes a 10-year epidemiology forecast for the diagnosed incident cases of acute hepatitis C and diagnosed prevalent cases of chronic hepatitis C. The diagnosed incident cases of acute hepatitis C among men and women are segmented by sex, age (three years and older), genotype (genotypes 1-6), and cases that have been treated.
• The diagnosed prevalent cases of chronic hepatitis C are segmented by sex, age (three years and older), genotype, cirrhosis status, coinfection (hepatitis B and HIV), and cases that have been treated. Additionally, the report provides estimated incident cases of acute hepatitis C and total prevalent cases of chronic hepatitis C.

Reasons to Buy

The Hepatitis C Epidemiology series will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global Hepatitis C markets.
• Quantify patient populations in the global Hepatitis C markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hepatitis C therapeutics in each of the markets covered.
• Understand magnitude of the Hepatitis C population by age, sex, genotype, cirrhosis status, coinfection, and treated status.